Guarneri et al., 2021 - Google Patents
Protective immunity in swine induced by Porcine Circovirus 2b inactivated vaccines with different antigen payloadGuarneri et al., 2021
View PDF- Document ID
- 7960354216609136201
- Author
- Guarneri F
- Tresoldi E
- Sarli G
- Boniotti M
- Lelli D
- Barbieri I
- Bacci B
- D’Annunzio G
- Amadori M
- Publication year
- Publication venue
- Veterinary Microbiology
External Links
Snippet
Abstract Porcine Circovirus 2 (PCV2) vaccines are poorly standardized in terms of antigen payload and correlates of protection. Therefore, twenty, 45-day old piglets were divided into four groups of 5 animals each and vaccinated with 800/266/88/0 nanograms, respectively, of …
- 229960005486 vaccines 0 title abstract description 57
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA Viruses
- C12N2750/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA Viruses ssDNA Viruses
- C12N2750/10011—Circoviridae
- C12N2750/10051—Methods of production or purification of viral material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA Viruses
- C12N2750/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA Viruses ssDNA Viruses
- C12N2750/10011—Circoviridae
- C12N2750/10061—Methods of inactivation or attenuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Opriessnig et al. | Comparison of efficacy of commercial one dose and two dose PCV2 vaccines using a mixed PRRSV–PCV2–SIV clinical infection model 2–3-months post vaccination | |
| Opriessnig et al. | A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naive pigs under experimental conditions | |
| Fort et al. | Porcine circovirus type 2 (PCV2) vaccination of conventional pigs prevents viremia against PCV2 isolates of different genotypes and geographic origins | |
| Opriessnig et al. | Effect of porcine parvovirus vaccination on the development of PMWS in segregated early weaned pigs coinfected with type 2 porcine circovirus and porcine parvovirus | |
| Segalés et al. | The natural history of porcine circovirus type 2: from an inoffensive virus to a devastating swine disease? | |
| Park et al. | Evaluation of a porcine circovirus type 2a (PCV2a) vaccine efficacy against experimental PCV2a, PCV2b, and PCV2d challenge | |
| McKeown et al. | Effects of porcine circovirus type 2 (PCV2) maternal antibodies on experimental infection of piglets with PCV2 | |
| Opriessnig et al. | Porcine circovirus type 2 infection decreases the efficacy of a modified live porcine reproductive and respiratory syndrome virus vaccine | |
| Opriessnig et al. | Comparison of the effectiveness of passive (dam) versus active (piglet) immunization against porcine circovirus type 2 (PCV2) and impact of passively derived PCV2 vaccine-induced immunity on vaccination | |
| Tomás et al. | A meta-analysis on experimental infections with porcine circovirus type 2 (PCV2) | |
| CN102971425A (en) | Live attenuated chimeric porcine circovirus vaccine | |
| US20120164170A1 (en) | Porcine Circovirus Type 2 (PCV2), Immunogenic Composition Containing the Same, Test Kit, and Application Thereof | |
| Trible et al. | Antibody responses following vaccination versus infection in a porcine circovirus-type 2 (PCV2) disease model show distinct differences in virus neutralization and epitope recognition | |
| Figueras-Gourgues et al. | Effect of Porcine circovirus 2 (PCV-2) maternally derived antibodies on performance and PCV-2 viremia in vaccinated piglets under field conditions | |
| Lyoo et al. | Comparative efficacy of three commercial PCV2 vaccines in conventionally reared pigs | |
| Opriessnig et al. | Porcine circovirus type 2 (PCV2)-infection and re-inoculation with homologous or heterologous strains: virological, serological, pathological and clinical effects in growing pigs | |
| Steiner et al. | Cellular adaptive immune response against porcine circovirus type 2 in subclinically infected pigs | |
| Madson et al. | Effect of porcine circovirus type 2 (PCV2) vaccination of the dam on PCV2 replication in utero | |
| Opriessnig et al. | Effect of porcine circovirus type 2a or 2b on infection kinetics and pathogenicity of two genetically divergent strains of porcine reproductive and respiratory syndrome virus in the conventional pig model | |
| Kim et al. | Evaluation of novel recombinant porcine circovirus type 2d (PCV2d) vaccine in pigs naturally infected with PCV2d | |
| Li et al. | Inactivated chimeric porcine circovirus (PCV) 1-2 vaccines based on genotypes 2b and 2d exhibit similar immunological effectiveness in protecting pigs against challenge with PCV2b strain 0233 | |
| Opriessnig et al. | Limited susceptibility of three different mouse (Mus musculus) lines to Porcine circovirus-2 infection and associated lesions | |
| Opriessnig et al. | A Porcine circovirus type 2b (PCV2b)-based experimental vaccine is effective in the PCV2b-Mycoplasma hyopneumoniae coinfection pig model | |
| Chen et al. | A prospective CSFV-PCV2 bivalent vaccine effectively protects against classical swine fever virus and porcine circovirus type 2 dual challenge and prevents horizontal transmission | |
| Guarneri et al. | Protective immunity in swine induced by Porcine Circovirus 2b inactivated vaccines with different antigen payload |